DK1004320T3 - Anvendelse af magnesium (Mg2+) til forbedring af genadministration ved genterapi - Google Patents

Anvendelse af magnesium (Mg2+) til forbedring af genadministration ved genterapi

Info

Publication number
DK1004320T3
DK1004320T3 DK99119057T DK99119057T DK1004320T3 DK 1004320 T3 DK1004320 T3 DK 1004320T3 DK 99119057 T DK99119057 T DK 99119057T DK 99119057 T DK99119057 T DK 99119057T DK 1004320 T3 DK1004320 T3 DK 1004320T3
Authority
DK
Denmark
Prior art keywords
gene
magnesium
administration
improve
gene therapy
Prior art date
Application number
DK99119057T
Other languages
Danish (da)
English (en)
Inventor
Serge Braun
Original Assignee
Transgene Sa
Ass Fr Contre Les Myopathies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene Sa, Ass Fr Contre Les Myopathies filed Critical Transgene Sa
Application granted granted Critical
Publication of DK1004320T3 publication Critical patent/DK1004320T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
DK99119057T 1998-09-30 1999-09-30 Anvendelse af magnesium (Mg2+) til forbedring af genadministration ved genterapi DK1004320T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP98402424A EP0998945A1 (de) 1998-09-30 1998-09-30 Verwendung von Magnesium (Mg2+) zur Erhöhung der Gen-Verabreichung bei Gentherapie

Publications (1)

Publication Number Publication Date
DK1004320T3 true DK1004320T3 (da) 2003-09-15

Family

ID=8235506

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99119057T DK1004320T3 (da) 1998-09-30 1999-09-30 Anvendelse af magnesium (Mg2+) til forbedring af genadministration ved genterapi

Country Status (10)

Country Link
US (2) US20020019357A1 (de)
EP (2) EP0998945A1 (de)
JP (1) JP5172054B2 (de)
AT (1) ATE243531T1 (de)
AU (1) AU767294B2 (de)
CA (1) CA2284399C (de)
DE (1) DE69909041T2 (de)
DK (1) DK1004320T3 (de)
ES (1) ES2201611T3 (de)
PT (1) PT1004320E (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6875748B2 (en) 2000-04-21 2005-04-05 Vical Incorporated Compositions and methods for in vivo delivery of polynucleotide-based therapeutics
EP1249244A1 (de) 2001-04-13 2002-10-16 Universiteit Gent Therapeutische Zusammensetzungen zur Behandlung einer g-actin / f-actin-gleichgewicht vermittelten Erkrankung, z.b. einer respiratorischen Erkrankung
WO2003000908A1 (en) * 2001-06-21 2003-01-03 Ecole Polytechnique Federale De Lausanne A method for introducing a nucleic acid into a eukaryotic cell
EP1270733A1 (de) * 2001-06-21 2003-01-02 Ecole Polytechnique Federale De Lausanne Verfahren zum Einbringen von Nukleinsäure in eukaryotische Zellen
WO2004075924A1 (ja) * 2003-01-17 2004-09-10 Japan Genome Solutions, Inc. 遺伝子導入促進剤およびそれを含む遺伝子導入用組成物
ATE500267T1 (de) 2003-07-21 2011-03-15 Transgene Sa Multifunktionelle cytokine
DE102005007744A1 (de) * 2004-06-24 2006-01-19 Shf Communication Technologies Ag Planetengetriebe zur Kombination unterschiedlicher Energiequellen
GB0817393D0 (en) * 2008-09-23 2008-10-29 Givaudan Sa Flavour
WO2010105135A1 (en) * 2009-03-13 2010-09-16 Tufts University Methods, apparatuses, and kits for introducing genetic material into living cells
EP3587455A1 (de) 2012-10-23 2020-01-01 Emory University Gm-csf- und il-4-konjugate, zusammensetzungen und zugehörige verfahren
WO2019222666A1 (en) * 2018-05-17 2019-11-21 University Of Florida Research Foundation, Incorporated Methods and compositions for using metal elements in aav gene therapy
WO2020061528A1 (en) 2018-09-21 2020-03-26 University Of Connecticut Compositions and methods to restore paternal ube3a gene expression in human angelman syndrome

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60188069A (ja) * 1984-03-08 1985-09-25 Nakano Vinegar Co Ltd 酢酸菌の環状ｄνａ導入法
US4798789A (en) * 1984-10-05 1989-01-17 Dnax Research Institute Of Molecular And Cellular Biology, Inc. cDNA clones coding for polypeptides exhibiting murine interleukin-2 activity
US5693622A (en) * 1989-03-21 1997-12-02 Vical Incorporated Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5593972A (en) * 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
FR2710074B1 (fr) * 1993-09-15 1995-12-08 Rhone Poulenc Rorer Sa Gène GRB3-3, ses variants et leurs utilisations.
US5844107A (en) * 1994-03-23 1998-12-01 Case Western Reserve University Compacted nucleic acids and their delivery to cells
FR2724665B1 (fr) * 1994-09-16 1996-12-20 Rhone Poulenc Rorer Sa Procede de production de proteines recombinantes, plasmides et cellules modifiees
JPH08308573A (ja) * 1995-05-19 1996-11-26 Ube Ind Ltd 細胞への遺伝子導入方法及びそれに用いられるウィルス感染培地
US5958684A (en) * 1995-10-02 1999-09-28 Van Leeuwen; Frederik Willem Diagnosis of neurodegenerative disease
US5994316A (en) * 1996-02-21 1999-11-30 The Immune Response Corporation Method of preparing polynucleotide-carrier complexes for delivery to cells
US6544523B1 (en) * 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
US5830698A (en) * 1997-03-14 1998-11-03 Idec Pharmaceuticals Corporation Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same
FR2763958A1 (fr) * 1997-05-29 1998-12-04 Transgene Sa Produit de combinaison associant un acide nucleique a une substance desorganisant la matrice extracellulaire pour la therapie genique
AU752658B2 (en) * 1998-05-06 2002-09-26 Association Francaise Contre Les Myopathies Use of a nuclease inhibitor or interleukin-10 (IL-10) for the preparation of a therapeutic composition for improving transfection of a polynucleotide into a cell and compositions useful in gene therapy

Also Published As

Publication number Publication date
US6881724B2 (en) 2005-04-19
EP1004320B1 (de) 2003-06-25
JP5172054B2 (ja) 2013-03-27
CA2284399A1 (en) 2000-03-30
ES2201611T3 (es) 2004-03-16
US20020019357A1 (en) 2002-02-14
CA2284399C (en) 2011-01-18
AU767294B2 (en) 2003-11-06
AU5139799A (en) 2000-04-06
JP2000143549A (ja) 2000-05-23
DE69909041T2 (de) 2004-04-01
EP1004320A1 (de) 2000-05-31
US20020156045A1 (en) 2002-10-24
ATE243531T1 (de) 2003-07-15
EP0998945A1 (de) 2000-05-10
DE69909041D1 (de) 2003-07-31
PT1004320E (pt) 2003-10-31

Similar Documents

Publication Publication Date Title
DK1004320T3 (da) Anvendelse af magnesium (Mg2+) til forbedring af genadministration ved genterapi
GR3035797T3 (en) Compositions useful for transferring therapeutically active substances into a target cell, and their use in gene therapy
ZA937459B (en) Pharmaceutical composition
HUP9801207A2 (hu) Nukleinsavat tartalmazó készítmények, előállításuk és alkalmazásuk
WO1996021470A3 (en) Compositions of nucleic acid and viscosity-increasing polymers for use in gene therapy
CA2346438A1 (en) Utilisation of dialkylfumarates for treating host-versus-graft reactions and auto-immune diseases
IL133585A0 (en) Soluble prodrugs of paclitaxel
CA2346119A1 (en) A method of inducing or enhancing chondrogenesis with extracellular matrix containing gdf-5
IL82084A0 (en) 1,4-diazepines,their preparation and pharmaceutical compositions containing them
YU19399A (sh) Lokalni anestetik za spoljnu upotrebu
IL136101A0 (en) Pharmaceutical compositions containing azelaic acid
ATE184788T1 (de) Idebenone-haltige zusammensetzungen zur behandlung von m. alzheimer
AU6889196A (en) Long active composition for rectal administration
ATE220912T1 (de) Herstellung von st1435 enthaltenden pharmazeutischen zusammensetzungen zur topischen verwendung
ES2180729T3 (es) Tratamiento terapeutico combinado de las patologias hiperproliferantes.
NO158677C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive isoksazol-derivater.
IE832680L (en) Nitrosourea derivatives.
ES2150305T3 (es) Composicion anhidra a base de lactulosa.
AU527523B2 (en) Hexahydro-1,4-oxazepines
BE1002099A3 (fr) Nouvelles quinazolinones tetracycliques, leur preparation et leur utilisation comme medicaments.
IT1291307B1 (it) Composizione farmaceutica atta al trattamento delle patologie neurodegenerative
KR880011160A (ko) 벤조피라노피리딘아세트산 에스테르화합물 및 그의 약학적 용도
AU2699195A (en) Biotin compounds for targetting tumors and sites of infection
CA2175337A1 (en) Method and Composition for Treatment of Patients Having Decompensated Liver Disease
SU1608870A1 (ru) Способ лечения кистозных новообразований челюсти